PPIDT00070
Drug Information
| Name | Botulinum toxin type A |
|---|---|
| Sequence | MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL |
| DrugBank_ID | DB00083 |
| Type | biotech |
| Indication | Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.[L32559] In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus,[L32494] and disorders of the 7th cranial nerve.[L32569] Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain[A231874], neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.[A231879] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Parenteral |
100.000 U
|
| Injection, powder, for solution | Intramuscular |
125 U
|
| Injection, powder, for solution | Intramuscular |
|
| Injection, powder, for solution | — |
100 IU
|
| Injection, powder, for solution | — |
200 IU
|
| Powder | Intramuscular |
100 unit/1vial
|
| Powder, for solution | Intramuscular |
100 unit / vial
|
| Powder, for solution | Intramuscular |
200 unit / vial
|
| Injection | Intramuscular |
100 U
|
| Injection, powder, for solution | Intradermal; Intramuscular |
100 units
|
| Injection, powder, for solution | Intradermal; Intramuscular; Subcutaneous |
200 Units
|
| Injection, powder, for solution | Intradermal; Intramuscular; Subcutaneous |
50 Units/vial
|
| Injection, powder, for solution | Intradermal; Intramuscular |
200 U
|
| Solution | Intramuscular |
100 UI
|
| Injection, powder, for solution | Intramuscular |
500 unit/1vial
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
300 U
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
500 UI
|
| Injection, powder, lyophilized, for solution | Intramuscular |
300 [USP'U]/1
|
| Solution | Intramuscular |
500.000 U
|
| Injection, powder, for solution | — |
300 unit/1vial
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
30000000 U
|
| Injection, solution | Intramuscular |
500 U
|
| Powder, for solution | Intramuscular |
300 unit / vial
|
| Injection, powder, for solution | — |
500 U
|
| Powder, for solution | Intramuscular |
500 unit / vial
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
50000000 U
|
| Powder | Intramuscular |
200 unit/1vial
|
| Powder | Intramuscular |
50 unit/1vial
|
| Injection, powder, for solution | — |
50 IU
|
| Solution | Intramuscular |
100 U
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
50 U
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
100 IU
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
10000000 IU
|
| Injection, powder, lyophilized, for solution | Intramuscular |
20000000 IU
|
| Injection, powder, for solution | Intramuscular |
100 U
|
| Injection, powder, for solution | Intramuscular |
50 U
|
| Injection, powder, lyophilized, for solution | Intramuscular; Subcutaneous |
5000000 U
|
| Injection, powder, for solution | Parenteral |
4 AU/0.1ml
|
| Injection, powder, for solution | Parenteral |
4 AU/ 0.1 ml
|
| Solution | Parenteral |
50.000 U
|
| Injection, powder, for solution | Parenteral |
100 U
|
| Injection, powder, for solution | Parenteral |
200 U
|
| Injection, powder, for solution | Parenteral |
50 U
|
| Powder, for solution | Intramuscular |
50 unit / vial
|
| Injection, powder, for solution | — |
|
| Injection, powder, for solution | — |
50 LD50 Units
|
| Injection, powder, for solution | Intramuscular |
100 LD50 units
|
| Injection, powder, for solution | Intramuscular |
50 LD50 units
|
| Injection, powder, lyophilized, for solution | Intramuscular |
100 U
|
| Injection, powder, lyophilized, for solution | Intramuscular |
10000000 U
|
| Injection, powder, lyophilized, for solution | Intramuscular |
5000000 U
|
| Injection, powder, for solution | — |
100 unit/1vial
|
| Injection, powder, lyophilized, for solution | — |
100 unit/1vial
|
| Injection, powder, for solution | — |
50 unit/1vial
|
Target Information